← Product Code [LLZ](/productcode/LLZ) · K262462 # TheraSphere 360™ Y-90 Management Platform (K262462) _Boston Scientific Corporation · LLZ · Jul 24, 2026 · Radiology · SESE_ **Canonical URL:** https://fda-staging.innolitics.com/device/K262462 ## Device Facts - **Applicant:** Boston Scientific Corporation - **Product Code:** [LLZ](/productcode/LLZ.md) - **Decision Date:** Jul 24, 2026 - **Decision:** SESE - **Submission Type:** Special - **Regulation:** 21 CFR 892.2050 - **Device Class:** Class 2 - **Review Panel:** Radiology - **Attributes:** Software as a Medical Device ## Indications for Use The TheraSphere 360™ Y-90 Management Platform includes Treatment Planning and Activity Calculation functionalities as optional interactive tools intended for calculating the activity of TheraSphere Y-90 Microspheres required at treatment time based upon the desired dose, lung shunt fraction, anticipated residual waste, and liver mass. The Treatment Planning and Activity Calculation functionalities include features to aid in TheraSphere Y-90 Microspheres dose vial selection. Additionally, the TheraSphere 360 Platform includes optional post-treatment analysis functionalities to be used following treatment with TheraSphere Y-90 Microspheres. For post-TheraSphere Y-90 Microspheres treatment, the TheraSphere 360 Platform should only be used for the retrospective determination of dose and should not be used to prospectively calculate dose or for pre-treatment planning when there is a need for retreatment using TheraSphere Y-90 Microspheres. ## Device Story Browser-based platform supporting radioembolization therapy; provides interactive tools for calculating Y-90 microsphere activity based on desired dose, lung shunt fraction, residual waste, and liver mass. Used by authorized clinicians for treatment planning, dose vial selection, and retrospective post-treatment dose analysis. Operates via MIRD (Medical Internal Radiation Dose) schema to transform clinical inputs into activity requirements. Facilitates clinical decision-making by ensuring accurate dose calculation and inventory management. Benefits patients by supporting precise delivery of radiation therapy. ## Clinical Evidence No clinical data. Performance evaluation consisted of bench testing, including software verification (unit and integration testing), cybersecurity evaluation, and design validation to ensure requirements and user needs were met. ## Technological Characteristics Browser-based software platform; utilizes MIRD (Medical Internal Radiation Dose) schema for dosimetry calculations. Functions include treatment planning, activity calculation, vial selection, and post-treatment analysis. Software version V2.1.0. ## Regulatory Identification A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements. ## Special Controls *Classification.* Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern). ## Predicate Devices - TheraSphere 360™ Y-90 Management Platform ([K260479](/device/K260479.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} FDA U.S. FOOD & DRUG ADMINISTRATION July 24, 2026 Boston Scientific Corporation Amy Mckinney Fellow, Regulatory Affairs 300 Boston Scientific Way Marlboro, Massachusetts 01752 Re: K262462 Trade/Device Name: TheraSphere 360™ Y-90 Management Platform Regulation Number: 21 CFR 892.2050 Regulation Name: Medical Image Management And Processing System Regulatory Class: Class II Product Code: LLZ Dated: July 17, 2026 Received: July 17, 2026 Dear Amy Mckinney: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov {1} K262462 - Amy Mckinney Page 2 Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory- {2} K262462 - Amy Mckinney Page 3 assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, Lora D. Weidner, Ph.D. Assistant Director Radiation Therapy Team DHT8C: Division of Radiological Imaging and Radiation Therapy Devices OHT8: Office of Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {3} | Indications for Use | | | | --- | --- | --- | | Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K262462 | ? | | Please provide the device trade name(s). | | ? | | TheraSphere 360™ Y-90 Management Platform | | | | Please provide your Indications for Use below. | | ? | | The TheraSphere 360™ Y-90 Management Platform includes Treatment Planning and Activity Calculation functionalities as optional interactive tools intended for calculating the activity of TheraSphere Y-90 Microspheres required at treatment time based upon the desired dose, lung shunt fraction, anticipated residual waste, and liver mass. | | | | The Treatment Planning and Activity Calculation functionalities include features to aid in TheraSphere Y-90 Microspheres dose vial selection. | | | | Additionally, the TheraSphere 360 Platform includes optional post-treatment analysis functionalities to be used following treatment with TheraSphere Y-90 Microspheres. For post-TheraSphere Y-90 Microspheres treatment, the TheraSphere 360 Platform should only be used for the retrospective determination of dose and should not be used to prospectively calculate dose or for pre-treatment planning when there is a need for retreatment using TheraSphere Y-90 Microspheres. | | | | Please select the types of uses. | ☑ Prescription Use (21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ? | | Please select the age group(s) for which the device(s) is to be used. | ☐ Neonates/Newborns (Birth to < 29 days old) ☐ Infants (29 days old to < 2 years old) ☐ Children (2 years old to < 12 years old) ☐ Adolescents (12 years old to < 22 years old) ☑ Adults (22 years old and greater) | ? | {4} # **K262462 510(k) SUMMARY** A summary of 510(k) safety and effectiveness information in accordance with the requirements of 21 CFR 807.92. | **Submitter:** | Boston Scientific Corp. | | --- | --- | | **Company Contact Person:** | Ms. Amy E McKinney, MS, RAC Fellow, Regulatory Affairs Boston Scientific Corp | | Phone: | 651-287-5096 | | Email: | Amy.mckinney@bsci.com | | **Alternate Contact Person:** | Ms. Janet Bukovcan Director, Regulatory Affairs Boston Scientific Corp. | | Phone: | 613-866-9312 | | Email: | Janet.bukovcan@bsci.com | | **Device Name:** | TheraSphere 360™ Y-90 Management Platform | | **Device Classification Name:** | Medical image management and processing system (LLZ) 21 CFR 892.2050 | | **Review Panel:** | Radiology | | **Predicate Devices / Reference 510(k):** | TheraSphere 360™ Y-90 Management Platform (K260479) | | **Date of Preparation:** | July 17, 2026 | # **Device Description:** The TheraSphere 360 Y-90 Management Platform is an end-to-end, browser-based platform that will host a wide range of resources (e.g. radioembolization activity calculations, ordering, tracking, and education) that support Authorized Users of TheraSphere Microspheres. The TheraSphere 360 Platform includes treatment planning functionality, activity calculation functionality, vial selection and ordering, and post-treatment analysis functionality. The treatment planning functionality and the activity calculation functionality include an interactive tool intended for calculating the activity of TheraSphere Microspheres required at the treatment time based upon the desired dose, lung shunt fraction, anticipated residual waste, and liver mass. The Vial Selector function allows users to select and order TheraSphere Microspheres dose vials from inventory that match desired results. The post-treatment analysis functionality is intended as an optional tool for post-treatment evaluation following TheraSphere Microspheres treatment. Page 1 of 3 {5} K262462 – Page 2 of 3 # Indications For Use: No changes were made to the Indications for Use. The TheraSphere 360™ Y-90 Management Platform includes Treatment Planning and Activity Calculation functionalities as optional interactive tools intended for calculating the activity of TheraSphere Microspheres required at treatment time based upon the desired dose, lung shunt fraction, anticipated residual waste, and liver mass. The Treatment Planning and Activity Calculation functionalities include features to aid in TheraSphere Microspheres dose vial selection. Additionally, the TheraSphere 360 Platform includes optional post-treatment analysis functionalities to be used following treatment with TheraSphere Microspheres. For post-TheraSphere Microspheres treatment, the TheraSphere 360 Platform should only be used for the retrospective determination of dose and should not be used to prospectively calculate dose or for pre-treatment planning when there is a need for retreatment using TheraSphere Microspheres. # Technological Comparison: This Special 510(k) was submitted for TheraSphere 360 V2.1.0 software. Changes in this 510(k) included a modification to update the dose calculations for vials in the vial selector cart when a user has modified the activity calculator inputs after placing vials in the cart. Other minor software anomalies were corrected as well that did not impact the functionality of the device. The table below provides a summary comparison of the submitted device compared to the predicate device: | Characteristic | TheraSphere™ 360 Y-90 Management Platform V2.1.0 | TheraSphere™ 360 Y-90 Management Platform V2.0 | Comment | | --- | --- | --- | --- | | Indications for Use | The TheraSphere 360 Y-90 Management Platform includes Treatment Planning and Activity Calculation functionalities as optional interactive tools intended for calculating the activity of TheraSphere Microspheres required at treatment time based upon the desired dose, lung shunt fraction, anticipated residual waste, and liver mass. The Treatment Planning and Activity Calculation functionalities include features to aid in TheraSphere Microspheres dose vial selection. Additionally, the TheraSphere | The TheraSphere 360 Y-90 Management Platform includes Treatment Planning and Activity Calculation functionalities as optional interactive tools intended for calculating the activity of TheraSphere Microspheres required at treatment time based upon the desired dose, lung shunt fraction, anticipated residual waste, and liver mass. The Treatment Planning and Activity Calculation functionalities include features to aid in TheraSphere Microspheres dose vial selection. Additionally, the TheraSphere 360 Platform includes optional post-treatment analysis functionalities to be used following treatment with | Identical | {6} K262462 – Page 3 of 3 | Characteristic | TheraSphere™ 360 Y-90 Management Platform V2.1.0 | TheraSphere™ 360 Y-90 Management Platform V2.0 | Comment | | --- | --- | --- | --- | | | 360 Platform includes optional post-treatment analysis functionalities to be used following treatment with TheraSphere Microspheres. For post-TheraSphere Microspheres treatment, the TheraSphere 360 Platform should only be used for the retrospective determination of dose and should not be used to prospectively calculate dose or for pre-treatment planning when there is a need for retreatment using TheraSphere Microspheres. | TheraSphere Microspheres. For post-TheraSphere Microspheres treatment, the TheraSphere 360 Platform should only be used for the retrospective determination of dose and should not be used to prospectively calculate dose or for pre-treatment planning when there is a need for retreatment using TheraSphere Microspheres. | | | Principles of Operation | Medical Internal Radiation Dose (MIRD) schema for dosimetry calculations | Medical Internal Radiation Dose (MIRD) schema for dosimetry calculations | Identical | | Device Functionalities | Contains medical device functionalities which utilize radioembolization activity calculations to determine the dose of TheraSphere Microspheres required at treatment time. | Contains medical device functionalities which utilize radioembolization activity calculations to determine the dose of TheraSphere Microspheres required at treatment time. | Identical | ## Summary of Performance Data Performance testing confirmed that the TheraSphere 360 V2.1.0 software performs safely and effectively and does not introduce any new or different safety risks. The TheraSphere 360 V2.1.0 medical device functions underwent software verification testing, including unit and integration testing and cybersecurity evaluation, to ensure that the product meets the defined software requirements. A design validation evaluation was conducted to ensure that the platform meets defined user needs. Verification and validation testing, including a usability evaluation, successfully demonstrated that the medical device functions and algorithms meet requirements and user needs, confirming safety and effectiveness of TheraSphere 360 V2.1.0 software and substantial equivalence to the predicate device. Clinical testing was not required to validate TheraSphere 360 V2.1.0 software. ## Conclusion: In conclusion, the TheraSphere 360 Y-90 Management Platform V2.1.0 medical device functions were evaluated against the predicate device and found to be substantially equivalent on the basis that 1) the indications for use are unchanged, and 2) the technology of the TheraSphere 360 Platform medical device functions is the same as the predicate device and no new or different issues of safety and effectiveness were raised. --- **Source:** [https://fda-staging.innolitics.com/device/K262462](https://fda-staging.innolitics.com/device/K262462) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com